Cord Blood News Volume 4.21 | May 31 2012

Inhibitory Receptors Bind ANGPTLs and Support Blood Stem Cells and Leukemia Development
Researchers showed that the immune-inhibitory receptor human leukocyte immunoglobulin-like receptor B2 (LILRB2) and its mouse orthologue paired immunoglobulin-like receptor (PIRB) are receptors for several angiopoietin-like proteins (ANGPTLs). LILRB2 and PIRB are expressed on human and mouse hematopoietic stem cells (HSCs), respectively, and the binding of ANGPTLs to these receptors supported ex vivo expansion of HSCs. [Nature] Abstract

Use of Human Umbilical Cord Blood Mononuclear Cells to Prevent Perinatal Brain Injury: A Pre-Clinical Study
Scientists investigated the potential of human umbilical cord blood mononuclear cells to prevent or repair brain lesions in an animal model of excitotoxic brain injury. [Stem Cells Dev] Abstract

Suppression of Erythroid Development In Vitro by Plasmodium vivax
To better understand the role of Plasmodium vivax infection in anemia, the inhibition of erythropoiesis using hematopoietic stem cells was investigated. Hematopoietic stem cells/CD34+ cells, isolated from normal human cord blood were used to generate growing erythroid cells. [Malar J] Abstract

HHV-6 Reactivation and Associated Sequelae after Hematopoietic Cell Transplantation
Scientists found that human herpesvirus 6 (HHV-6) reactivation was independently and quantitatively associated with increased risk of subsequent cytomegalovirus reactivation, acute graft-versus-host-disease, and mortality after allogeneic hematopoietic cell transplantation. [Biol Blood Marrow Transplant] Abstract

Melatonin Inhibits IL-1β-Induced MMP-9 Expression and Activity in Human Umbilical Vein Endothelial Cells via Suppressing Nuclear Factor-κB Activation
Researchers investigated the protective effect of melatonin in human umbilical vein endothelial cells (HUVECs) monolayer permeability and the regulation of matrix metalloproteinase 9 (MMP-9) induced by IL-1β in HUVECs. [J Endocrinol] Abstract

Angptl4 Maintains In Vivo Repopulation Capacity of CD34+ Human Cord Blood Cells
Human CD34⁺ cells from cord blood were cultured in vitro for eleven or eight days in the presence or absence of Angiopoietin-like (Angptl) growth factors. The reconstitution capacity of expanded cells was subsequently measured in vivo by transplantation into NOD-SCID or NSG mice, and compared to that of uncultured cells. [Eur J Haematol] Abstract

Effect of Preeclampsia and Intrauterine Growth Restriction on Endothelial Progenitor Cells in Human Umbilical Cord Blood
The authors evaluated the influence of prematurity, preeclampsia and intrauterine growth restriction on the endothelial progenitor cell population in human umbilical cord blood. [J Matern Fetal Neonatal Med] Abstract

Susceptibility of Cord Blood Antioxidant Enzymes Glutathione Reductase, Glutathione Peroxidase and Glutathione S-Transferase to Different Antibiotics: In Vitro Approach
Researchers purified human cord blood glutathione reductase, glutathione S-transferase and human cord blood glutathione peroxidase from human cord blood erythrocytes and analyzed the inhibition effects of the antibiotics incorporating cefuroxime, ceftriaxone, ceftizoxime and cefoperazone, on these enzymes. [J Enzyme Inhib Med Chem] Abstract

ThermoGenesis Announces AABB Accreditation for Beike Biotech
ThermoGenesis Corp. announced that its customer Beike Biotechnology Co., Ltd. (Beike) has become the first company in China to receive accreditation from the AABB (formerly the American Association of Blood Banks). Beike produces a full line of products derived from umbilical cord tissue, cord blood and bone marrow stem cells. [Beike Biotechnology Co., Ltd.] Press Release

ICMS and AABB Collaborate to Help Improve Safety for Patients Receiving Autologous Adult Cell-Based Therapies
The International Cellular Medicine Society (ICMS) and AABB (formerly the American Association of Blood Banks) announced that AABB will be assisting ICMS in the development of quality-based, voluntary standards for the collection, processing and administration of autologous adult cells. [AABB] Press Release

Top Stem Cell Scientist and Pediatrician Recruited to Ottawa
World-renowned scientist and pediatrician Dr. Bernard Thébaud will soon be in Ottawa to pursue his goal of using stem cells to repair the lungs of premature babies. [Ottawa Hospital Research Institute] Press Release

White House Petitioned to Make Research Free to Access
More than 17,000 people have signed an online petition urging US President Barack Obama to require all scientific journal articles resulting from US taxpayer-funded research to be made freely available online. [White House, United States] Press Release

Horizon 2020: A €80 Billion Battlefield for Open Access
As negotiations proceed to shape the next installment of Europe’s gargantuan research funding programs, scientists, librarians, and publishers are eagerly awaiting the answer to a critical question: How strong will the new seven-year program, called Horizon 2020, be on Open Access? [European Commission, European Union] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Business Development Manager – Stem Cell (SynGen Inc.)

Controller (SynGen Inc.)

Director: Regulatory Affairs (SynGen Inc.)

Manufacturing Manager (SynGen Inc.)

Chief Scientific Officer (SynGen Inc.)

Development Scientist – Cell Therapy (GE Healthcare)

Group Leaders, Principle Scientists – Stem Cell Clinical Product R&D (Shanghai Hengrui Pharmaceuticals Co., Ltd)

Histocompatibility & Immunogenetics Service Development Scientist (NHS Blood and Transplant)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.